Navigation Links
Initiation of Coverage Informational Review Issued by Scimitar Equity Research
Date:12/17/2007

BOSTON, Dec. 17 /PRNewswire/ -- Scimitar Equity Research, Inc. issues a review on Nventa Biopharmaceuticals Corporation (TSX: NVN) entitled: "A Very Promising Therapeutic and Vaccine Candidate for the Treatment of Diseases Caused by the Human Papillomavirus (HPV)." The analyst research is available on Scimitar's website: http://www.scimitarequity.com.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

About HspE7, Nventa's Lead Product Candidate:

HspE7 is a novel therapeutic vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Heat shock proteins (Hsps), also known as stress proteins, are naturally present in the human body and play important roles in the immune system, including transporting substances within cells and activating cells of the immune system.

Scimitar Equity Research, Inc. provides equity research of emerging healthcare companies for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about NVN.TO (TSX) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This sponsored analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity Research, Inc.

Henry W. McCusker

Director of Research

phone: (617) 559.1080

fax: (617) 559.1083

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... AVIV, Israel , May 19, 2016 ... or the "Company"), an emerging global ophthalmic company focused ... product candidates which address ophthalmic conditions, announced today that ... Italy ) for the manufacturing, distribution, ... product for the treatment of dry eye syndrome (DES) ...
(Date:5/19/2016)... At the 18 th International Leksell Gamma ... , (May 15-19), Elekta announced that Leksell Gamma ... been used in the treatment of more than one ... functional disorders. Today, Gamma Knife surgery is ... hundreds of leading hospitals and clinics around the world. ...
(Date:5/19/2016)... -- The equities market is never short of ... is without doubt the Healthcare space. ActiveWallSt.com has uncovered four ... Alkermes PLC (NASDAQ: ALKS ), AMAG Pharmaceuticals Inc. ... IDXX ), and Atossa Genetics Inc. (NASDAQ: ... http://www.activewallst.com/ On Wednesday, Alkermes PLC,s ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... After graduating from Cornell, author Joshua Alexander ... hospitals, on medication, living on Social Security disability and staying in a group home. ... Beat It!” (published by Balboa Press), Alexander shares how he was finally able to ...
(Date:5/24/2016)... Colorado (PRWEB) , ... May 24, 2016 , ... ... architecture firm, announces the grand opening of ‘El Centro del Quinto Sol Wheel ... of the Pueblo ‘east side’ community to offer something special for this often ...
(Date:5/24/2016)... ... 24, 2016 , ... NutraPre today announced the nationwide release ... to prevent morning sickness and promote overall heath. Engineered with advanced nanotechnology, this ... of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO Eddie Cameron ...
(Date:5/23/2016)... ... 23, 2016 , ... According to an article published May 12th on the Medical ... health and hygiene. The article points out that, as long as patients are brushing as ... worn and frayed. Of course, these worn-out bristles won’t clean teeth and gum tissue as ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical ... representatives from the Japan PMDA, US FDA, industry and academia at the ... help format data from clinical trials so that it can be shared and ...
Breaking Medicine News(10 mins):